Ajanta Pharma reports strong Q2 FY 2026 results, declares interim dividend

Ajanta Pharma Limited's board of directors, at their meeting on November 3, 2025, approved a first interim dividend of ₹28 per share for FY 2026, totaling ₹349.82 crore. The record date for this dividend is fixed for Monday, November 10, 2025, with payments scheduled on or after November 20, 2025. This decision follows a strong financial period, with consolidated revenue from operations increasing by 14% to ₹1,354 crore in Q2 FY 2026 and by 14% to ₹2,656 crore for H1 FY 2026 compared to the previous year.

Profit after tax (PAT) rose by 20% to ₹260 crore in Q2 FY 2026 and by 12% to ₹516 crore for H1 FY 2026. The company’s branded generics segment reported a 12% growth in India (₹432 crore) and 5% in Asia (₹310 crore) for Q2 FY 2026, contributing to a healthy 8% overall growth for branded generics. Notably, the US Generics segment saw a substantial 48% increase to ₹344 crore in Q2 FY 2026.

The company's R&D expenses for H1 FY 2026 stood at 5% of revenue, amounting to ₹119 crore. Ajanta Pharma remains committed to expanding its product portfolio, with 19 new product launches in H1 FY 2026 in emerging markets and 10 new launches in India during the same period.